In Setback For Mylan, Judge Upholds Levaquin Patent

Law360, New York (January 2, 2005, 12:00 AM EST) -- A federal judge has barred Mylan Laboratories Inc. from making a generic version of the antibiotic Levaquin until at least December 2010.

Last week, U.S. District Judge Irene M. Keeley prohibited Mylan from making or selling levofloxacin tablets, a generic form of Levaquin.

The drug is used to treat a variety of conditions, including bronchitis, sinusitis and urinary tract infections.

Ortho-McNeil Pharmaceutical Inc., a Johnson & Johnson company that sells Levaquin in the U.S., and Japanese patent-owner Daiichi Pharmaceutical Co. had filed their first lawsuit in...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.